lopinavir + ritonavir + saquinavir + indinavir + ritonavir + nelfinavir

This combination refers to a group of HIV-1 protease inhibitors (PIs) used in the management of HIV infection, particularly within the context of highly active antiretroviral therapy (HAART). The components include lopinavir, ritonavir, saquinavir, indinavir, and nelfinavir. These drugs function by binding to the active site of the HIV-1 protease enzyme, thereby preventing the processing of viral gag-pol polyprotein precursors into individual functional proteins required for the assembly of infectious viral particles. Ritonavir is frequently co-administered in low doses as a pharmacokinetic enhancer (booster) because it is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes other protease inhibitors. This specific grouping of PIs has been studied in clinical trials, such as those conducted by the HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), to evaluate long-term clinical and immunological outcomes in pediatric HIV patients.

Brand names

Kaletra

Other names

LPV/rProtease Inhibitors